1. 2020
  2. Impact of nitisinone treatment and discontinuation on the metabolome of wildtype and hereditary tyrosinemia type 1 mice

    Colemonts-Vroninks, H., Norman, B., Davison, A., Neuckermans, J., Marcélis, L., Mortier, A., De Bundel, D., Ranganath, L., Martens, G., Vanhaecke, T., Gallagher, J. & De Kock, J., 17 Apr 2020, p. FRI284.

    Research output: Unpublished contribution to conferencePosterResearch

  3. Directed protein evolution as a tool to innovate gene therapy for hereditary tyrosinemia type 1

    Neuckermans, J., Colemonts-Vroninks, H., Marcélis, L., Mertens, A., Schwaneberg, U. & De Kock, J., Mar 2020.

    Research output: Unpublished contribution to conferencePosterResearch

  4. 2019
  5. A robust bacterial assay for high-throughput screening of human 4-hydroxyphenylpyruvate dioxygenase inhibitors

    Neuckermans, J., Mertens, A., Schwaneberg, U. & De Kock, J., 2 Oct 2019, In : Scientific Reports. 9, 1, p. 14145 11 p.

    Research output: Contribution to journalArticleResearchpeer-review

  6. 2018
  7. Engineering of a potent nitisinone-insensitive HPD enzyme by directed protein evolution.

    Neuckermans, J., Mertens, A., De Kock, J. & Schwaneberg, U., 25 Apr 2018, (Unpublished).

    Research output: Unpublished contribution to conferencePosterResearch

  8. 2017
  9. ESTABLISHMENT OF THE OPTIMAL MRNA ELECTROPORATION PROTOCOL FOR HUMAN SKIN-DERIVED MESENCHYMAL STEM CELLS

    Neuckermans, J., Branson, S., Heirman, C., Vanhaecke, T., Rogiers, V. & De Kock, J., 28 Mar 2017, (Unpublished).

    Research output: Unpublished contribution to conferencePosterResearch

  10. Establishment of the optimal mRNA electroporation protocol for human skin-derived mesenchymal stem cells

    Neuckermans, J., 2017, (Unpublished).

    Research output: Unpublished contribution to conferenceOtherResearch

ID: 11741442